SEARCH

SEARCH BY CITATION

References

  • 1
    Schindeler A, McDonald MM, Bokko P, Little DG. Bone remodeling during fracture repair: the cellular picture. Semin Cell Dev Biol. 2008 Oct; 19(5):45966.
  • 2
    Marsell R, Einhorn TA. The biology of fracture healing. Injury. 2011; 42(6):5515.
  • 3
    McDonald MM, Dulai S, Godfrey C, Amanat N, Sztynda T, Little DG. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling. Bone. 2008 Oct; 43(4):65362.
  • 4
    Li C, Mori S, Li J, Kaji Y, Akiyama T, Kawanishi J, Norimatsu H. Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. J Bone Miner Res. 2001; 16:42936.
  • 5
    Amanat N, Brown R, Bilston LE, Little DG. A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair. J Orthop Res. 2005 Sep; 23(5):102934.
  • 6
    Amanat N, McDonald M, Godfrey C, Bilston L, Little DG. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res. 2007 Jun; 22(6):86776.
  • 7
    Li J, Mori S, Kaji Y, Mashiba T, Kawanishi J, Norimatsu H. Effect of bisphosphonate (incadronate) on fracture healing of long bones in rats. J Bone Miner Res. 1999 Jun; 14(6):96979.
  • 8
    Cao Y, Mori S, Mashiba T, Westmore MS, Ma L, Sato M, Akiyama T, Shi L, Komatsubara S, Miyamoto K, Norimatsu H. Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res. 2002 Dec; 17(12):223746.
  • 9
    Manabe T, Mori S, Mashiba T, Kaji Y, Iwata K, Komatsubara S, Yamamoto T. Effect of dosing interval duration of intermittent ibandronate treatment on the healing process of femoral osteotomy in a rat fracture model. Calcif Tissue Int. 2012; 90:193201.
  • 10
    Gerstenfeld LC, Sacks DJ, Pelis M, Mason ZD, Graves DT, Barrero M, Ominsky MS, Kostenuik PJ, Morgan EF, Einhorn TA. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res. 2009; 24(2):196208.
  • 11
    Bukata SV. Systemic administration of pharmacological agents and bone repair: what can we expect. Injury. 2011 Jun; 42(6):6058.
  • 12
    Einhorn TA. The science of fracture healing. J Orthop Trauma. 2005 Nov-Dec; 19(10 Suppl):S46.
  • 13
    McDonald MM, Morse A, Peacock L, Mikulec K, Schindeler A, Little DG. Characterization of the bone phenotype and fracture repair in osteopetrotic incisors absent rats. J Orthop Res. 2011 May; 29(5):72633.
  • 14
    Flick LM, Weaver JM, Ulrich-Vinther M, Abuzzahab F, Zhang X, Dougall WC, Anderson D, O Keefe RJ, Schwarz EM. Effects of receptor activator of NFjB (RANK) signaling blockade on fracture healing. J Orthop Res. 2003; (21):67684.
  • 15
    Colnot C, Thompson Z, Miclau T, Werb Z, Helms JA. Altered fracture repair in the absence of MMP9. Development. 2003; 130(17):412333.
  • 16
    Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol. 2003 Jul; 200(4):44864.
  • 17
    Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med. 2005 Apr-Jun; 9(2):26785.
  • 18
    Ortega N, Wang K, Ferrara N, Werb Z, Vu TH. Complementary interplay between matrix metalloproteinase-9, vascular endothelial growth factor and osteoclast function drives endochondral bone formation. Dis Model Mech. 2010; 3:22435.
  • 19
    Behonick DJ, Xing Z, Lieu S, Buckley JM, Lotz JC, Marcucio RS, Werb Z, Miclau T, Colnot C. Role of matrix metalloproteinase 13 in both endochondral and intramembranous ossification during skeletal regeneration. PLoS One. 2007 Nov 7;2(11):e1150.
  • 20
    Yamagiwa H, Tokunaga K, Haylani T, Hatano H, Uchidna M, Endo N, Takahashi HE. Expression of metalloproteinase-13 (collagenase-3) is induced during fracture healing in mice. Bone. 1999; 25(2):197203.
  • 21
    Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 1998 May 1; 93(3):41122.
  • 22
    Everts V, Korper W, Hoeben KA, Jansen ID, Bromme D, Cleutjens KB, Heeneman S, Peters C, Reinheckel T, Saftig P, Beertsen W. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J Bone Miner Res. 2006 Sep; 21(9):1399408.
  • 23
    Sawae Y, Sahara T, Sasaki T. Osteoclast differentiation at growth plate cartilage-trabecular bone junction in newborn rat femur. J Electron Microsc (Tokyo). 2003; 52(6):493502.
  • 24
    Pelletier JP, Boileau C, Brunet J, Boily M, Lajeunesse D, Reboul P, Laufer S, Martel-Pelletier J. The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. Bone. 2004 March; 34(3):52738.
  • 25
    Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone. 1999 Jul; 25(1):97106.
  • 26
    Kellinsalmi M, Mönkkönen H, Mönkkönen J, Leskelä HV, Parikka V, Hämäläinen M, Lehenkari P. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts. Basic Clin Pharmacol Toxicol. 2005 Dec; 97(6):38291.
  • 27
    Ulrich-Vinther M, Andreassen TT. Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength. Calcif Tissue Int. 2005; 76:2806.
  • 28
    Bonnarens F, Einhorn TA. Production of a standard closed fracture in laboratory animal bone. J Orthop Res. 1984; 2(1):97101.
  • 29
    Ota N, Takaishi H, Kosaki N, Takito J, Yoda M, Tohmonda T, Kimura T, Okada Y, Yasuda H, Kawaguchi H, Matsumoto M, Chiba K, Ikegami H, Toyama Y. Accelerated cartilage resorption by chondroclasts during bone fracture healing in osteoprotegerin-deficient mice. Endocrinology. 2009 Nov; 150(11):482334.
  • 30
    Harding AK, W-Dahl A, Geijer M, Toksvig-Larsen S, Tägil M. A single bisphosphonate infusion does not accelerate fracture healing in high tibial osteotomies: a randomized study of 46 patients. Acta Orthopaedica. 2011; 82(4):46570.
  • 31
    Silvano Adami, Cesar Libanati, Steven Boonen, Steven RCummings, Pei-Ran Ho, Andrea Wang, Ethel Siris, Joseph Lane. Denosumab Treatment in Postmenopausal Women With Osteoporosis Does Not Interfere With Fracture Healing: Results From the FREEDOM Trial. JBJS. Epub Oct. 24 2012.
  • 32
    Zijlstra A, Aimes RT, Zhu D, Regazzoni K, Kupriyanova T, Seandel M, Deryugina EI, Quigley JP. Collagenolysis-dependent angiogenesis mediated by matrix metalloproteinase-13 (collagenase-3). J Biol Chem. 2004; 279(26):2763345.
  • 33
    Uusitalo H, Hiltunen A, Soderstrom M, Aro HT, Vuorio E. Expression of cathepsins B, H, K, L, and S and matrix metalloproteinases 9 and 13 during chondrocyte hypertrophy and endochondral ossification in mouse fracture callus. Calcif Tissue Int. 2000; 67:38290.
  • 34
    Kosaki N, Takaishi H, Kamekura S, Kimura T, Okada Y, Minqi L, Amizuka N, Chung U, Nakamura K, Kawaguchi H, Toyama Y, D'Armiento J. Impaired bone fracture healing in matrix metalloproteinase-13 deficient mice. Biochem Biophys Res Commun. 2007; 354:84651.
  • 35
    Lieu S, Hansen E, Dedini R, Behonick D, Werb Z, Miclau T, Marcucio R, Colnot C. Impaired remodeling phase of fracture repair in the absence of matrix metalloproteinase-2. Dis Model Mech. 2011; 4:20311.
  • 36
    Sorsa T, Ramamurthy NS, Vernillo AT, Zhang X, Konttinen YT, Rifkin BR, Golub LM. Functional sites of chemically modified tetracyclines: inhibition of the oxidative activation of human neutrophil and chicken osteoclast pro-matrix metalloproteinases. J Rheumatol. 1998 May; 25(5):97582.
  • 37
    Wigner NA, Kulkarni N, Yakavonis M, Young M, Tinsley B, Meeks B, Einhorn TA, Gerstenfeld LC. Urine matrix metalloproteinases (MMPs) as biomarkers for the progression of fracture healing. Injury. 2012 Mar; 43(3):2748.
  • 38
    Smith EJ, McEvoy A, Little DG, Baldock PA, Eisman JA, Gardiner EM. Transient retention of endochondral cartilaginous matrix with bisphosphonate treatment in a long-term rabbit model of distraction osteogenesis. J Bone Miner Res. 2004 Oct; 19(10):1698705.
  • 39
    Kidd LJ, Cowling NR, Wu AC, Kelly WL, Forwood MR. Bisphosphonate treatment delays stress fracture remodeling in the rat ulna. J Orthop Res. 2011 Dec; 29(12):182733.
  • 40
    Kim N, Odgren PR, Kim DK, Marks SC Jr, Choi Y. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci U S A. 2000 Sep 26; 97(20):1090510.
  • 41
    Mori S. Fracture healing with anti-resorptive agents. J Musculoskelet Neuronal Interact. 2003; 3(4):3146.